Major Ingredients

Each vial contains 16.7ml solution containing Paclitaxel USP 30 mg (6 mg/ml)

Major Functionality

Ontaxel is indicated as first line and subsequent therapy for the treatment of advanced carcinoma of the ovary.As first line therapy,Ontaxel is indicated in combination with cisplatin. Breast carcinoma: Ontaxel is indicated for the adjuvant treatment of node positive breast cancer administered sequentially to standard doxorubicincontaining combination chemotherapy. Ontaxel is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracline unless clinically contraindicated. Ontaxel is indicated for the first line therapy of advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracline therapy is suitable or in combination with trastuzumab in patients who over express HER-2 at a 2+ or 3+ level as determined by immunohistochemistry. Gemoxen, in combination of Ontaxel .is indicated in the treatment of patients with unresectable,locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. Ontaxel is indicated for the treatment of metastatic cancer of the breast,in combination with trastuzumab (Herceptin), in patients who have tumors that over-express HER-2 and who have not received previous chemotherapy for their metastatic disease. Non Small Cell Lung Carcinoma: Ontaxel, in combination with cisplatin, is indicated for the first line treatment of non small cell lung cancer in patients who are not candidates for potential curative surgery and/or radiation therapy. Kaposi's Saocoma: Ontaxel is indicated for the second line treatment of AIDS related Kaposi's Sarcoma. Gastric Carcinoma: Ontaxel is indicated for the treatment of Gastric Carcinoma. Dosage & Administration: All patients should be premedicated prior to paclitaxel

Manufacture Information

Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.